Otsuka's first-half pharma sales constrained by currency effects
This article was originally published in Scrip
Otsuka Holdings has released its first financial results under the disclosure requirements that it is now governed by as a listed company. The Japanese group floated on the Tokyo Stock Exchange on 15 December, raising around $2.4 billion.
You may also be interested in...
Novel antibody-drug conjugate receives approval in Japan for second-line breast cancer, providing another push to Japanese firm’s strategic plan to build up its oncology operations.
Collaboration with fundraising Tokyo-based venture builds mid-sized firm's interest in cell-based therapies in a highly supportive regulatory environment.
New long-term clinical data with Takeda’s dengue vaccine contender show a durable response against all four serotypes and support the dosing regimen in an ongoing pivotal study.